120 results on '"Bosch, Jaime"'
Search Results
2. Donor Simvastatin Treatment Is Safe and Might Improve Outcomes After Liver Transplantation: A Randomized Clinical Trial
3. Reply
4. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis
5. A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis
6. Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease
7. Reply
8. A Prognostic Strategy Based on Stage of Cirrhosis and HVPG to Improve Risk Stratification After Variceal Bleeding
9. Characterization and Proteome of Circulating Extracellular Vesicles as Potential Biomarkers for NASH
10. Reply
11. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials
12. Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte‐Mediated Paracrine Mechanism
13. Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension
14. Preemptive‐TIPS Improves Outcome in High‐Risk Variceal Bleeding: An Observational Study
15. Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension
16. Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease
17. Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease
18. Reply
19. Statins in cirrhosis—Ready for prime time
20. Reply
21. Reply
22. Simvastatin Attenuates Liver Injury in Rodents with Biliary Cirrhosis Submitted to Hemorrhage/Resuscitation
23. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases
24. Reply
25. Reply
26. Reply
27. Beta-blockers in 2016: Still the safest and most useful drugs for portal hypertension?
28. Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis
29. Primary prophylaxis of variceal bleeding in children and the role of MesoRex Bypass: Summary of the Baveno VI Pediatric Satellite Symposium
30. Prognosis of acute variceal bleeding: Is being on beta‐blockers an aggravating factor? A short‐term survival analysis
31. The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique
32. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta‐analysis
33. Reply
34. Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats
35. Use of noninvasive markers of portal hypertension and timing of screening endoscopy for gastroesophageal varices in patients with chronic liver disease
36. Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study
37. Use of non-invasive markers of portal hypertension and timing of screening endoscopy for gastroesophageal varices in patients with chronic liver disease
38. Carvedilol for preventing recurrent variceal bleeding: Waiting for convincing evidence
39. Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: A case-control study
40. Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction
41. Cardiovascular Risk Factors and Systemic Endothelial Function in Patients With Cirrhosis
42. New therapeutic paradigm for patients with cirrhosis
43. Erratum: Noninvasive Prediction of Clinically Significant Portal Hypertension and Esophageal Varices in Patients With Compensated Liver Cirrhosis
44. Addition of simvastatin to cold storage solution prevents endothelial dysfunction in explanted rat livers
45. Reply
46. Reply
47. Response to Talwalkar
48. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis
49. A Specialized, Nurse-Run Titration Clinic: A Feasible Option for Optimizing β-Blockade in Non–Clinical Trial Patients
50. NCX-1000, a Nitric Oxide–Releasing Derivative of UDCA, Does Not Decrease Portal Pressure in Patients With Cirrhosis: Results of a Randomized, Double-Blind, Dose-Escalating Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.